SCHEMBL5558059

SCHEMBL5558059

[CH2]CCCCCNC(=O)[C@@H](N)CS

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 3/20 0.48
FNTB P49356 3/20 0.48
RRM1 P23921 1/20 0.47
DPP7 Q9UHL4 2/20 0.47
PGGT1B P53609 2/20 0.46
GNAI3 P08754 1/20 0.45
GNAO1 P09471 1/20 0.45
GNAI1 P63096 1/20 0.45
ALDH1A2 O94788 1/20 0.44
ALDH1A1 P00352 1/20 0.44
ALDH2 P05091 1/20 0.44
ALDH1A3 P47895 1/20 0.44
S1PR2 O95136 2/20 0.42
S1PR1 P21453 2/20 0.42
S1PR3 Q99500 2/20 0.42
S1PR5 Q9H228 1/20 0.42
MMP2 P08253 1/20 0.40
PTGS1 P23219 1/20 0.39
SLC7A11 Q9UPY5 1/20 0.39
TLR2 O60603 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2452784 0.85 GNAI3 (0.61) FNTAFNTBRRM1DPP7PGGT1B
SCHEMBL18807791 0.85 FNTA (0.48) FNTAFNTBRRM1DPP7PGGT1B
SCHEMBL930389 0.85 DPP7 (0.50) FNTAFNTBRRM1DPP7PGGT1B
SCHEMBL19385712 0.84 MMP2 (0.47) FNTAFNTBRRM1DPP7PGGT1B
SCHEMBL5654571 0.84 DPP7 (0.69) FNTAFNTBRRM1DPP7PGGT1B
SCHEMBL9491467 0.84 DPP7 (0.69) FNTAFNTBRRM1DPP7PGGT1B
SCHEMBL9491462 0.84 DPP7 (0.69) FNTAFNTBRRM1DPP7PGGT1B
SCHEMBL930618 0.82 DPP7 (0.47) FNTAFNTBRRM1DPP7PGGT1B
SCHEMBL14854295 0.82 FNTA (0.55) FNTAFNTBRRM1DPP7PGGT1B
SCHEMBL14854237 0.82 FNTA (0.55) FNTAFNTBRRM1DPP7PGGT1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578962-A4 CARRIER-LIGAND FUSIONS AND USES THEREOF NEW ENGLAND BIOLABS INC (US) 2007-03-14 EP disclosed
EP-1578962-A2 CARRIER-LIGAND FUSIONS AND USES THEREOF NEW ENGLAND BIOLABS, INC. (US) 2005-09-28 EP disclosed
US-20040198958-A1 Carrier-ligand fusions and uses thereof NEW ENGLAND BIOLABS, INC. 2004-10-07 US disclosed
WO-2004053460-A2 CARRIER-LIGAND FUSIONS AND USES THEREOF NEW ENGLAND BIOLABS, INC. (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198958-A1 Carrier-ligand fusions and uses thereof SCLY, LANCL1, SELENOI FNTA 110/4885FNTB 41/4885RRM1 2703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.